## min read

MTHFR Gene Mutation: What It Means for Mental Health

By

Sonia Garcia

|

October 17, 2026

Summarize with AI

MTHFR Gene Mutation: What It Means for Mental Health

Table of Contents

Example H2
Example H3
Example H4
Example H5
Example H6

Maybe a genetic report flagged it. Maybe a friend, a forum, or a supplement ad told you it could explain your fatigue, your depression, or why medication never quite worked. Now you're wondering what an MTHFR gene mutation actually means for you.

MTHFR variants are extremely common. Most people who carry them have no health effects at all, and research linking them to mental health conditions shows a real but small association, not a cause. Medical experts don't recommend routine testing for them.

What the MTHFR gene does

The MTHFR gene carries instructions for an enzyme called methylenetetrahydrofolate reductase. That enzyme converts folate, a B vitamin, into the active form your body uses to turn the amino acid homocysteine into methionine. According to MedlinePlus Genetics, the active form, 5-methyltetrahydrofolate, is the main form of folate found in blood.

When the enzyme works less efficiently, homocysteine can build up. That's the mechanism behind most of the interest in MTHFR, including the mental health questions.

C677T, A1298C, heterozygous, and homozygous

Most people searching "MTHFR gene mutation" are really asking about two common variants:

  • C677T. The most common and best studied. At position 677 in the gene, the DNA base C is replaced by T. The resulting enzyme is less stable and less active, especially in people with two copies.
  • A1298C. The second common variant. The CDC notes there isn't enough evidence that A1298C on its own significantly affects how the body processes folate.

You inherit one copy of the gene from each parent, which is where the lab terms come from:

  • Heterozygous means one copy carries the variant (for C677T, written CT).
  • Homozygous means both copies carry it (TT).
  • Compound heterozygous means one copy of C677T and one copy of A1298C.

These variants are so common they're closer to normal human variation than to a disease. The CDC reports that more people in the U.S. have one or two copies of C677T than don't. Having both copies is less common: MedlinePlus estimates about 25% of Hispanic people and 10% to 15% of North American white people carry two copies of C677T.

MTHFR symptoms: what the variant does and doesn't cause

Most people with common MTHFR variants have no symptoms. Cleveland Clinic puts it plainly: MTHFR gene variants most often don't affect your health or cause symptoms. When they do matter, it's usually through higher homocysteine or lower folate, and mostly in people with two copies of C677T. Even then, how much folate you get from food matters more than your genotype.

That's different from what you'll read on many wellness sites, which attribute everything from fatigue to brain fog to MTHFR. There's no reliable evidence for a list of "MTHFR symptoms" in people with the common variants. If you have symptoms, they deserve an evaluation, not an assumption that a gene variant explains them.

There is one important exception. Rare, severe mutations in the MTHFR gene cause homocystinuria, a serious inherited condition whose symptoms usually appear early in life. Most U.S. newborns are screened for it shortly after birth. That's a different situation from the common C677T and A1298C variants.

MTHFR and mental health: what research shows

Because MTHFR sits in the folate and methylation pathway, researchers have looked hard for links to psychiatric conditions. The findings are consistent in one way: the effect is modest.

  • Depression. A 2013 meta-analysis of 26 studies, with 4,992 people with depression and 17,082 controls, found that two copies of C677T were associated with higher odds of depression (odds ratio 1.42). The link was stronger in Asian populations, marginal in white populations, and absent in older adults.
  • Schizophrenia, bipolar disorder, and depression combined. A 2011 meta-analysis of case-control studies with 29,502 participants found TT carriers had modestly higher odds of these conditions as a group (odds ratio 1.26). The authors read this as evidence of a shared genetic vulnerability across the three conditions.

An odds ratio of 1.26 to 1.42 is a small increase in relative risk for a very common genotype. Most people with two copies of C677T never develop depression, bipolar disorder, or schizophrenia, and most people with those conditions don't have two copies. Mental health conditions come from many genes and life experiences acting together. MTHFR is, at most, one small piece.

Folate, folic acid, and methylfolate

A common online claim is that people with MTHFR variants can't use folic acid and need "methylated" supplements instead. The CDC says that isn't true: people with an MTHFR variant can process all types of folate, including folic acid. People with the TT genotype have blood folate levels only about 16% lower on average than people with CC at the same intake, and folic acid intake matters more than genotype in determining blood folate.

L-methylfolate, the active form, has been studied as an add-on to antidepressants. In two randomized trials published in the American Journal of Psychiatry in 2012, adults with depression that hadn't responded fully to an SSRI received L-methylfolate or placebo alongside their medication. The first trial, with 148 patients starting at 7.5 mg a day, found no difference. The second, with 75 patients at 15 mg a day, found a significant benefit over placebo. Both enrolled people based on their depression, not on a genetic test. Whether any add-on makes sense for a specific person is a clinical decision that depends on their full history.

For more on how folate and other nutrients relate to mood, see our article on nutrient deficiencies and anxiety.

Should you get tested for MTHFR?

For most people, no. MedlinePlus states that medical experts don't recommend testing for common MTHFR gene changes in most cases. A provider may order it in specific situations, such as high homocysteine on a blood test combined with a family history.

The American College of Medical Genetics and Genomics went further in a 2013 practice guideline: MTHFR polymorphism testing has minimal clinical utility and shouldn't be part of a routine evaluation for blood clotting disorders. Recent meta-analyses had disproven the links that originally motivated the testing.

If you already have a result, it's still useful context to share with your care team. It just isn't a diagnosis, and it isn't a treatment plan.

When depression or mood symptoms don't improve

People often look up MTHFR because something isn't working: depression that keeps coming back, medication that only half helps, or mood swings no one has explained. Those problems are real, even if MTHFR is unlikely to be the answer. They usually call for a fuller psychiatric evaluation: a closer look at the diagnosis, past medication trials, co-occurring conditions, sleep, substance use, and physical health.

That's the kind of care we provide at Amae Health. Our clinics specialize in conditions including Major Depressive Disorder, bipolar disorder, and schizophrenia. Our care teams bring psychiatrists, therapists, primary care physicians, and dietitians under one roof, so lab results, nutrition, and medication history are reviewed together, by people who share one treatment plan. See how our integrated outpatient clinics work.

Frequently asked questions

How common is the MTHFR gene mutation?

Very common. According to the CDC, more people in the U.S. have one or two copies of the C677T variant than don't. Two copies are less common, estimated at about 25% of Hispanic people and 10% to 15% of North American white people.

What are the symptoms of being MTHFR C677T heterozygous?

Usually none. According to MedlinePlus, raised homocysteine is seen mainly in people with two copies of C677T. If you have symptoms, they need an evaluation of their own rather than being attributed to one copy of a common variant.

Does MTHFR cause depression?

No single gene causes depression. Two copies of C677T are associated with modestly higher odds of depression in meta-analyses, with an odds ratio around 1.4, but most people who carry them never develop depression.

Do people with MTHFR need methylfolate instead of folic acid?

According to the CDC, no. People with MTHFR variants can process folic acid, and folic acid intake matters more than genotype for blood folate levels. L-methylfolate has been studied as an add-on treatment for depression, regardless of MTHFR status, and decisions about it belong with a clinician.

Is MTHFR testing worth it?

For most people, it isn't recommended. Medical genetics experts say the common variants have minimal clinical utility. A provider may order testing in specific cases, such as unexplained high homocysteine with a family history.

Key takeaways

  • An MTHFR gene mutation usually means one or two copies of the common C677T or A1298C variants, which most people carry without health effects.
  • Two copies of C677T can raise homocysteine and are linked to modestly higher odds of depression, bipolar disorder, and schizophrenia, but the effect is small.
  • People with MTHFR variants can process folic acid, and routine MTHFR testing isn't recommended.
  • If depression or mood symptoms aren't improving, a full psychiatric evaluation is more useful than a gene result.

If you or someone you love is living with depression, bipolar disorder, or schizophrenia that hasn't responded to treatment, request an intake appointment. Our team will walk you through how an evaluation works and what to bring, including any lab or genetic results you already have.

Reccomended for you

# min read

Schizophrenia Treatment Options: Navigating the Path to Recovery

By

Sonia Garcia

|

May 15, 2026

A schizophrenia diagnosis arrives to a person in a small room, and rearranges things without asking — the way a conversation feels, the way a plan for next year suddenly needs rewriting, the way someone you love looks at you and you can't quite tell what they're thinking anymore. Most of what you'll read about schizophrenia treatment options is either clinical to the point of cold, or optimistic in a way that skips the hard parts. 

Schizophrenia is a chronic condition. In 2026, it is also named one of the most treatable severe mental illnesses in psychiatry. The medications have quietly changed over the last two years, with the care models changing even faster. And the question clinicians now ask (is this person living a life they recognize as their own?) is a better question than the one psychiatry asked a generation ago.

This is a guide to what schizophrenia treatment actually looks like now.

What "Treatment" Means for Schizophrenia in 2026

For most of psychiatry's history, treating schizophrenia meant turning down the volume on hallucinations and delusions and hoping everything else would hold. Consequently, it often didn't. The older medications were blunt instruments — they could quiet the psychosis while leaving a person sedated, emotionally flat, and unable to concentrate. A patient could be symptom-free on paper and still lose their apartment, their job, and their social world, not because the illness had won, but because the treatment had taken too much with it.

That old goal has been replaced.

The modern target is functional recovery: the ability to live a connected, productive life, be it work or school. Rebuilding the relationships that came apart during the acute phase. Living on your own terms. Functional recovery is not the same as symptom elimination. Some of the people who reach it still hear voices, and some of the people with zero symptoms can't hold a routine. What functional recovery actually requires, almost without exception, is a care plan that treats medication, therapy, physical health, and social support as one whole problem instead of four.

Pharmacological Breakthroughs: A New Era of Medication

Medication is the floor of schizophrenia treatment, not the ceiling. For about 40 years, that floor was built of one material: antipsychotics that bind dopamine D2 receptors and block the signal. That is still the starting point for most patients in 2026. What has quietly changed is the field, which now has options that were not there two years ago.

Second-Generation Antipsychotics: The Current Standard

Risperidone, olanzapine, aripiprazole, paliperidone, quetiapine. Those are the names that will likely appear first in any conversation with a psychiatrist. They're called "second-generation" or "atypical" antipsychotics because together, they work on dopamine and serotonin, producing a more favorable profile for negative symptoms and cognitive effects than the drugs that came before them.

They work. They also come at a cost.

The trade-off is metabolic. Weight gain. Elevated blood sugar. Shifts in lipid panels that, untracked, add up to real cardiovascular risk over time. A care team that prescribes these medications without monitoring the body is doing half the job. Metabolic monitoring is not optional.

The Non-Dopaminergic Revolution: Cobenfy and Muscarinic Agonists

In September 2024, something happened in schizophrenia pharmacology for the first time in about 35 years. The FDA approved xanomeline-trospium (Cobenfy, formerly known as KarXT), and the mechanism was not a variation on the dopamine theme. Cobenfy works on muscarinic receptors (specifically the M1 and M4 subtypes), meaning the biological pathway it acts on is different in kind, not just in detail (Yale Medicine).

Here is why that matters.

Roughly one-third of patients don't respond adequately to dopamine-based medications. The metabolic and movement-related side effects of the older drugs are also downstream of dopamine blockade. Cobenfy doesn't block dopamine, which is why early trials suggest it may avoid some of that side effect profile.

Long-term data is still accumulating. For now, the field has its first new mechanism in a generation.

Long-Acting Injectables: Reducing the Daily Burden

Long-acting injectable antipsychotics, or LAIs, deliver a single dose that lasts weeks or even months. For patients whose relapses have traced back to missed pills, that is a meaningful shift.

The evidence has caught up with the intuition. A 2022 network meta-analysis in World Psychiatry pooled 92 randomized trials and 22,645 participants and found that LAIs hold up against daily oral antipsychotics in preventing relapse (Ostuzzi et al., 2022). Real-world studies of US Medicare patients have shown LAIs are associated with lower rates of psychiatric hospitalization and treatment discontinuation.

LAIs are not right for every patient. Some people find meaning in the daily ritual of a pill. Some have had painful experiences with injections. The right answer comes out of a real conversation with a psychiatrist who has the patient's history in front of them.

Models of Care: Why the Environment Matters

The same medication can produce very different outcomes depending on how it is delivered. Two patients on the same dose of the same drug can end up in very different places a year later. The difference is usually the system around them.

Coordinated Specialty Care (CSC)

In 2026, coordinated Specialty Care is the standard for early psychosis.It is also one of the clearest examples in psychiatry of a care model producing better outcomes than a new drug would. The American Psychiatric Association formally endorsed it in its 2020 practice guideline (APA Practice Guideline for the Treatment of Patients With Schizophrenia), and it came out of the NIMH RAISE research initiative.

The model is a single team of clinicians working from one plan: medication management, individual therapy, supported employment and education, family education, and case management that actually happens, rather than getting sent to five different offices on five different days.

The data is strong. In the NIMH RAISE Early Treatment Program, patients who received CSC had hospitalization rates of 23% compared with 44% in usual community care (NIMH: Team-based Treatment is Better for First Episode Psychosis). They were also more likely to stay in school or employment and experienced greater improvement in symptoms, interpersonal relationships, and quality of life (Kane et al., American Journal of Psychiatry, 2016).

That is a halving of hospitalization risk, produced by a care model rather than a new molecule.

CSC was built for early psychosis. For patients further along in treatment, other models fit better.

Integrated Outpatient Care for Severe Mental Illness

For patients past the first-episode window, integrated outpatient care takes the same principle as CSC and adapts it for the long haul. The model brings psychiatrists, therapists, primary care physicians, dietitians, health coaches, peer mentors, and clinical care coordinators under one roof, working from a single shared plan.

The problem it solves is fragmentation. In the usual picture, a patient has a psychiatrist at one office, a therapist at another, a primary care provider at a third, and if case management exists at all, it runs on lost email attachments. Small things become crises. Crises become hospitalizations. Hospitalizations become the next relapse.

But it doesn't have to work that way.

This is the model our integrated outpatient clinics are built on. We see adults 18 and older. Our care team is designed so that mental health, physical health, and everyday function are handled in the same place, by people who talk to each other. The patient is not the one running the coordination.

Crisis Services and Long-Term Stability

Crisis services are not long-term care, and long-term care is not crisis services. Inpatient hospitalization exists to keep people safe when symptoms are acute. It is essential, and it saves lives. But it is not designed to produce long-term stability, and the handoff from inpatient to outpatient is the highest-risk period for readmission. That handoff is where integrated outpatient care earns its keep.

Evidence-Based Psychosocial Interventions

Medication does one job well. It quiets the biology. Everything else is outside what a pill can do: how a person thinks about what is happening to them, how they rebuild relationships that came apart during the acute phase, how they get back into work or school.

That is where psychosocial interventions come in.

Cognitive Behavioral Therapy for Psychosis (CBTp)

CBT for Psychosis, usually shortened to CBTp, is not standard CBT with a few tweaks. It is a specialized protocol built from the ground up for people who hear voices, hold persistent unusual beliefs, or are trying to function while symptoms are still present. The APA practice guideline gives CBTp a 1B rating, which translates roughly to "the evidence is strong and clinicians should offer this" (APA Practice Guideline, 2020).

What CBTp actually does in a session is teach specific skills. Reality testing. Cognitive distancing from distressing voices. Stress-reduction techniques for the moments when symptoms spike. Coping strategies for persistent delusions that have not responded fully to medication. The goal is not to eliminate the symptoms. It is to change the relationship a person has with them.

Social Skills and Vocational Training

Skills erode during acute episodes. A patient who was holding a job six months ago and had friends two years ago can come back from a hospitalization and find that the conversational rhythm, the workplace reflexes, and the social scaffolding are all gone. Not permanently. Just not where they left them.

Structured social skills training is what it sounds like: deliberate practice. Starting conversations. Reading a room at work. Managing conflict without escalation. Re-entering relationships that went quiet during the acute phase. Supported employment programs pair these skills with real job coaching, and the evidence is that they help people get and keep work when traditional vocational rehabilitation has not.

Cognitive Remediation

Hallucinations and mood can stabilize while the harder, quieter symptoms persist: forgetting appointments, losing the thread of a conversation, struggling to plan a week. These are the symptoms that sit between "stable" and "back to a life I recognize." For many patients, they are what actually prevents the return to work or school.

Cognitive remediation is structured training for those skills. Memory exercises. Attention work. Executive function practice. The programs are not new, but they are one of the most underprescribed interventions in this space. They will not cure cognitive symptoms, but they can meaningfully improve day-to-day function.

The Role of Family and Community Support

No one recovers from schizophrenia alone. That is not a sentimental claim, but a finding that has been reproduced in study after study over several decades.

Family psychoeducation is one of the most consistently supported non-medication interventions in the books. The idea is simple: when the people a patient lives with understand what schizophrenia is, what the medications do, and how to communicate in hard moments, relapse rates drop. A concept in the research called "expressed emotion" describes a household climate marked by high levels of criticism, hostility, or emotional over-involvement. When that climate softens, relapse rates soften with it. Nothing about this says families cause schizophrenia. They don't. But the environment in which treatment either catches or slips is incredibly important.

Community reintegration carries the same weight. A stable apartment. A part-time job, even a small one. Peer support groups. A faith community if that fits. Friendships that survive the acute phase. These are not "lifestyle" factors that sit outside treatment. They are the treatment. A patient with housing and a routine has a very different clinical trajectory from the same patient without them.

How to Choose Among Schizophrenia Treatment Options

The question families ask us is almost never "should we get treatment." It is "how do we pick the right place." A few things matter more than the rest in that decision.

Start with the intake. A good assessment is not a form that takes 20 minutes to fill out. It is a conversation that covers psychiatric history, medication history and response, current symptoms, physical health, substance use, the home situation, and what the patient actually wants out of treatment. If the intake is structured as a checklist, the treatment plan will be too.

Ask how the team communicates. Is there a dedicated case manager? Does the psychiatrist read the therapist's notes? Is metabolic monitoring built into the schedule? Is family involvement standard? Are outcomes tracked? These are the questions we built our care model to answer, and a clinic that stumbles on them is worth a second look.

Insist on shared decision-making. A patient is a participant in their treatment, not a recipient of it. A good clinician lays out the trade-offs of each medication in plain language, listens to what the patient wants, and makes decisions alongside them. A clinician who rushes that or waves it off is telling you something.

Frequently Asked Questions

Q: Can schizophrenia be cured?

Not cured in the traditional sense. Schizophrenia is managed, which is a word that sounds smaller than it is. "Managed" in 2026 can mean living for decades with minimal disruption, working, keeping relationships, and needing medical care the way a person with diabetes does. Functional recovery is achievable for a meaningful number of patients, though not all.

Q: What happens if I stop taking my medication?

The risk of relapse rises sharply. What makes stopping tricky is the delay. Many people who discontinue antipsychotic medication feel fine for weeks, sometimes months, before symptoms return. That gap is long enough to conclude the medication wasn't necessary, and then to be caught off guard when symptoms do come back. Talk to your prescriber before making any changes.

Q: Are there natural treatments for schizophrenia?

Sleep, exercise, nutrition, and stress management support mental health and matter for anyone living with schizophrenia. They are not a substitute for medical treatment. If something is marketed as a "natural cure" for schizophrenia, that is a reason to stop reading. Supplements, herbs, and alternative therapies have not been shown to treat the underlying biology of the condition. Some interact with prescribed medications in ways that can be dangerous.

Q: How do I help a loved one who refuses treatment?

This is the question we hear most from families, and it is the hardest one. A few things help:

  • Anosognosia, a lack of awareness of one's illness, is itself a symptom of schizophrenia. It is not denial. Understanding the difference can change how you approach the conversation.
  • The LEAP method (Listen, Empathize, Agree, Partner), developed by Dr. Xavier Amador, was built for exactly these situations.
  • NAMI's Family-to-Family programs teach communication skills and connect families with others walking the same path.
  • In an acute safety crisis, call 988, the Suicide and Crisis Lifeline, or your local mobile crisis team.

Moving Toward Functional Recovery

A schizophrenia diagnosis is a serious event. It is not a verdict.

The range of schizophrenia treatment options has meaningfully widened since 2024. New medications. New evidence about old medications. Care models with strong outcomes data. Psychosocial interventions that help with the parts of recovery medication cannot touch. The clinical goal has moved from quieting the biology to helping a person live a life they recognize as their own.

What most patients and families need is not a single treatment.

They need a team that treats the whole picture, which means symptoms, physical health, relationships, work, and function, as one problem instead of four.

If you or someone you love is living with schizophrenia, schizoaffective disorder, or a related condition, Amae Health is here to talk. Our care teams include psychiatrists, therapists, primary care providers, dietitians, health coaches, peer mentors, and clinical care coordinators, all working from one shared plan. We see adults 18 and older at our clinics in Los Angeles, Los Altos, San Mateo, Raleigh, New York, and Brooklyn. To start the conversation, request an intake appointment.

‍

Citations

  1. 3 Things to Know About Cobenfy, Yale Medicine. Tier 4 (major academic medical center).
  2. Ostuzzi et al., "Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants," World Psychiatry, 2022. Tier 1 (peer-reviewed).
  3. Kane et al., "Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program," American Journal of Psychiatry, 2016. Tier 1 (peer-reviewed).
  4. NIMH: Team-based Treatment is Better for First Episode Psychosis. Tier 2 (government).

The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, 2020. Tier 3 (professional association).

# min read

What Is Quiet Borderline Personality Disorder (BPD)?

By

Sonia Garcia

|

October 14, 2026

From the outside, you look fine. You show up, you apologize first, you keep your voice level. Inside, a small comment from a friend can set off hours of shame, a spiral of "they're going to leave," and a quiet decision to pull away before anyone can hurt you. That pattern has a name people search for: quiet BPD. It describes borderline personality disorder (BPD) turned inward, where the intense emotions are real but almost nobody sees them.

Quiet BPD isn't a separate diagnosis. It's a way of describing how BPD can look when anger, fear, and despair are directed at yourself instead of at other people. And because it's so easy to miss, people often live with it for years before anyone names it.

Is quiet BPD a real diagnosis?

Not formally. The DSM-5 describes one borderline personality disorder, with no official subtypes. "Quiet BPD," "silent BPD," "internalized BPD," and "hidden BPD" are informal terms that patients and clinicians use for the same inward-facing pattern.

The idea has roots in research, though. Psychologist Theodore Millon described four subtypes of BPD, including a "discouraged" type and a "petulant" type. The discouraged type, marked by avoidant and dependent traits, unexpressed anger, guilt, and shame, is the closest match to what people now call quiet BPD. (We've written separately about the outward-facing petulant type of BPD.)

Newer data points the same way. A 2023 study of 109 patients with BPD in a psychiatric day clinic, published in Personality Disorders: Theory, Research, and Treatment, sorted patients into three groups by symptom pattern. Thirty-five fit an "internalizing" profile, and that group had more co-occurring mood disorders than the others.

So the label is informal. The pattern is not.

Quiet BPD symptoms and signs

The core symptoms of quiet BPD are the same ones the NIMH lists for borderline personality disorder. What changes is the direction they travel.

  • Fear of abandonment shows up as hypervigilance and pre-emptive withdrawal. You don't beg someone to stay. You leave first, or go silent, so the rejection can't land.
  • Intense, shifting moods happen behind a calm face. An episode can last a few hours to a few days, and the people around you may never know it happened.
  • Anger gets swallowed and turned into self-criticism. Instead of an outburst, there's a long internal prosecution of everything you did wrong.
  • An unstable sense of self feels like not knowing who you are without someone else's approval, and shape-shifting to fit whoever you're with.
  • Chronic emptiness can look like flatness or "I'm just tired" to everyone else.
  • Dissociation, feeling cut off from yourself or your surroundings, often under stress.
  • Rejection sensitivity: replaying a conversation for days, reading a short text as proof someone is done with you.
  • Self-harm or suicidal thoughts, kept hidden.

People with this presentation are often described as perfectionists, people-pleasers, or "the easy one" in the family. That's part of why the condition goes unrecognized.

Quiet BPD vs. "classic" BPD

The difference isn't severity. It's visibility.

In the presentation most people picture, distress spills outward: arguments, accusations, impulsive spending or drinking, visible crises in relationships. In quiet BPD, the same emotional storm happens internally. The person who might shout "you never cared about me" instead thinks "of course they don't care, I'm too much," and quietly stops replying to messages.

Both reflect the same underlying difficulty regulating emotions. Both cause real suffering. One is just far easier to overlook.

Why quiet BPD gets missed

Quiet BPD often arrives in a clinic labeled as something else, usually depression or anxiety. The internal pattern of shame, emptiness, and withdrawal overlaps heavily with both, and BPD frequently co-occurs with them: the NIMH notes that people with BPD may also experience depression, anxiety disorders, PTSD, eating disorders, and substance use disorders. If you're treated for depression alone and keep cycling back, the underlying pattern may not have been named. (For more on that overlap, see how anxiety and depression overlap.)

There's a second reason. People with quiet BPD are skilled at appearing okay, including in a therapist's office. They minimize. They worry about being a burden. A clinician who only sees the composed surface can miss what's underneath.

What causes quiet BPD?

No single cause explains BPD, quiet or otherwise. Genes and environment both contribute.

On the genetic side, a 2021 study of more than 1.8 million people in Swedish national registries estimated the heritability of diagnosed BPD at 46%. Risk was highest among identical twins and fell as relatives became more distant. The remaining variance came from environmental factors unique to each person.

On the environmental side, clinicians often hear about childhoods where feelings were dismissed, punished, or simply never acknowledged. Some people learned early that expressing anger or need made things worse, so they stopped. That's one plausible route from a sensitive temperament to an inward-facing pattern, though research hasn't yet separated what makes one person's BPD quiet and another's outward.

Self-harm and safety

Quiet doesn't mean low-risk. The NIMH notes that people with BPD are more likely to engage in self-harm, and the inward-facing pattern makes it easier to hide. Families sometimes learn about self-harm or suicidal thoughts only after a crisis.

If you or someone you love is having thoughts of suicide, call or text the 988 Suicide & Crisis Lifeline at 988. In an emergency, call 911.

Treatment for quiet BPD

BPD is treatable, and the evidence is strongest for specialized psychotherapy. A 2020 Cochrane review pooled 75 randomized trials with 4,507 participants. Across 22 trials comparing psychotherapy with usual care, therapy reduced BPD symptom severity. The two most-studied approaches were:

  • Dialectical behavior therapy (DBT), which was developed specifically for BPD and teaches skills for intense emotions, distress tolerance, and relationships.
  • Mentalization-based treatment (MBT), which builds the ability to understand your own and other people's mental states, especially under stress.

For quiet BPD, part of the work is simply making the inner experience visible: learning to notice and name anger, shame, and fear before they turn into silent withdrawal.

Medication plays a supporting role. According to the NIMH, the benefits of medication for BPD are unclear and it isn't a first-line treatment. Clinicians may use it alongside therapy for specific symptoms or co-occurring conditions such as depression.

Can quiet BPD get better?

Yes. There's no long-term research on quiet BPD specifically, but the data on BPD overall is more hopeful than most people expect. In a 10-year study of 290 adults with BPD first assessed during a psychiatric hospital stay, published in the American Journal of Psychiatry in 2010, 93% reached a symptom remission lasting at least two years. Full recovery, meaning remission plus good work and social functioning, was harder: about half got there. That gap is the case for treatment that goes beyond symptoms to rebuild relationships, work, and daily life.

How we treat BPD at Amae Health

Borderline Personality Disorder is one of the conditions our clinics specialize in. Our care teams bring psychiatrists, therapists, primary care physicians, peer mentors, and care coordinators under one roof, working from one treatment plan. For someone with quiet BPD, that matters: the more people who know your history, the harder it is for a composed surface to hide what's going on. Read more about how we approach care.

Frequently asked questions

Is quiet BPD real?

Yes, as a pattern. "Quiet BPD" isn't an official DSM-5 diagnosis, but it describes a recognized way borderline personality disorder can present, close to the "discouraged" subtype Theodore Millon described and the "internalizing" group seen in newer research.

Is there a test for quiet BPD?

There's no validated test for quiet BPD specifically. Online quizzes can prompt reflection, but a BPD diagnosis comes from a clinical evaluation by a mental health professional who looks at your history, patterns over time, and co-occurring conditions.

How is quiet BPD different from depression?

They overlap and often occur together. Depression centers on low mood and loss of interest. Quiet BPD adds intense fear of abandonment, an unstable sense of self, rapid shifts in mood, and relationship patterns driven by rejection sensitivity.

How can I help someone with quiet BPD?

Notice withdrawal instead of reading it as disinterest, and ask directly how they're doing. Avoid pressing for an explanation in the moment. Our guide on how to help someone with mental health issues covers more. If they mention self-harm or suicide, take it seriously and contact 988.

Key takeaways

  • Quiet BPD is an informal name for borderline personality disorder expressed inward: hidden anger, shame, withdrawal, and self-blame.
  • It's not a separate DSM-5 diagnosis, but research has identified a similar "internalizing" pattern.
  • It's often mistaken for depression or anxiety, and self-harm can stay hidden.
  • Specialized psychotherapy such as DBT and MBT has the strongest evidence, and long-term remission is common.

If you recognize yourself here, or you're worried about someone who seems fine but isn't, you can request an intake appointment. Our team will explain how an evaluation works and what to expect from your first visit.

# min read

Amae Health Featured on Advancements with Ted Danson

By

Sonia Garcia

|

February 4, 2025

We’re honored to share that Advancements with Ted Danson recently spotlighted Amae Health’s work in transforming mental health care for people with severe mental illness (SMI). This episode offers an inside look into our unique, outcome-driven approach that combines technology and compassionate care to support our members’ journeys toward lasting stability and a higher quality of life.

At Amae, we’re dedicated to providing more than just treatment. Our approach includes personalized therapy, medical support, lifestyle guidance, and a strong community connection. We’re committed to creating spaces where healing and growth are possible.

Catch the full story on Amazon Prime Video, Advancements Season 3, Episode 9, to see how we’re helping those who need it most.